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To the editor: 
 
 
The global overload that health systems are undergoing since the start of the COVID-19 
pandemic has forced hospitals to explore sustainable alternatives to treat vulnerable 
patients that require closer monitoring and higher use of resources, such as Kidney 
Transplant Recipients (KTRs)1,2.The use of telemedicine and hospital-like 
infrastructures represent a valid option for most patients with mild-moderate COVID-
19, as well as for patients in the recovery phase who cannot be discharged from 
hospital3,4.Herein we present our experience with KTRs infected by SARS-CoV-2 in the 
Hotel Salut (Health Hotel, HH), which was set-up within 2.5 km from the Hospital on 
March 25th 2020, coinciding with the main COVID-19 outbreak in Spain. At full 
capacity, the HH could accommodate up to 300 patients across 6 floors of 50 single-
rooms each floor. The HH was equipped with both human and material resources from 
the Hospital Clínic of Barcelona, including 24-hour medical and nurse attention, 
availability of high-flux oxygen, a pharmacy and the same IT equipment.  
 
By the end of May, 45 KTRs who were followed-up at our center developed COVID-
19, of which 28 were hospitalized at the Hospital Clínic. Twelve patients were 
transferred to the HH according to the following criteria: i) >6 days from symptoms 
onset, ii) temperature below 37.3°C, iii) Respiratory rate <22 per minute and FiO2 < 
0.35, iv) C-Reactive Protein< 5mg/dl or descending, LDH <240UI/L or descending, 
lymphocytes >1000/mm3 or increasing and v)without radiological progression. Baseline 
characteristics and treatment are highlighted in Table 1 and are described as median 
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Mann-Whitney test or Fisher’s exact test with SPSS 25.0 (SPSS inc, Chicago, US). The 
study has been approved by the local Ethical Committee (code HCB/2020/0641). The 
treatment protocol used in the HH was the same as the one carried out in the Hospital, 
and already described by our group5. Mycophenolate and/or mTOR inhibitors were 
discontinued in all patients. Calcineurin inhibitors were also suspended in case 
lopinavir/ritonavir was prescribed. KTRs were transferred to HH after 8.0[4.25-13.50] 
days of hospitalization; at that stage none of them had fever and 20% were still needing 
oxygen. Hospital stay was significantly shorter for patients treated at HH than for those 
discharged directly from the hospital (12.50[8.25-19.50] days, P=0.001). Median stay at 
the HH was 9.50[6.50-12.50] days, and only one patient was readmitted to the Hospital 
for respiratory deterioration 3 days after HH admission, being discharged from the 
hospital 9 days afterwards. Evolution of clinical parameters reflected progressive 
recovery after infection (Figure 1). It should be noted that stay at HH also allowed the 
gradual reintroduction of immunosuppression despite the challenging interactions 
between calcineurin inhibitors (CNIs) and the antiviral agents6,7. Therefore, tacrolimus 
was restarted 9[8- 11] days after withdrawal, with trough levels of 4.85[3.92-5.55]ng/ml 
at the time of HH discharge. The rest of immunosuppressant drugs were introduced 
gradually afterwards, tapering the steroids simultaneously.  
 
In conclusion, although our study was conducted among a small proportion of all the 
COVID-19 infected KTRs, treating them at a medicalized hotel facility allowed us to 
monitor their progress closely, thus obtaining positive clinical outcomes as well as the 
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Table 1 - Baseline characteristics and treatment of KTRs total population. Comparison between 
KTRs who were transferred to the Hotel Salut (Health Hotel, HH) and those who were 
discharged directly from the Hospital.  
 
Figure 1 – Evolution of COVID-19-related laboratory parameters before and after HH 
admission. 
 























Age 52.50 [46.25-68] 48.50 [43.75-57.25] 58 [47.25-72.75] 0.110 
Sex (% males) 18/28 (64.3%) 7/12 (58.3%) 11/16 (68.8%) 0.698 
Time from transplant 56.46 [22.01-125-45] 42.56 [12.21-74.75] 65.15 [26.11-134.92] 0.423 
Baseline immunosuppression 
   - TAC + MPA 14/28 (50.0%) 5/12 (41.7%) 9/16 (56.3%) 0.240 
   - TAC + mTORi 9/28 (32.1%) 6/12 (50.0%) 3/16 (18.8%) 
   - Other 5/28 (17.9%) 1/12 (8.3%) 4/16 (25.0%) 
Creatinine at baseline 
(mg/dl) 
1.55 [1.15-2.18] 1.93 [1.44-2.54] 1.29 [1.13-2.10] 0.093 
Positive PCR swab 
(%yes) 
23/28 (82.1%) 9/12 (75.0%) 14/16 (87.5%) 0.624 
Symptoms (%yes) 
   - Fever 26/28 (92.9%) 10/12 (83.3%) 16/16 (100.0%) 0.175 
   - Cough 18/28 (64.3%) 9/12 (75.0%) 9/16 (56.3%) 0.434 
   - Dyspnea 9/28 (32.1%) 2/12 (16.7%) 7/16(43.8%) 0.223 
   - Gastrointestinal 7/28 (25.0%) 2/12 (16.7%) 5/16 (31.3%) 0.662 
   - Dysgeusia  3/28 (10.7%) 1/12 (8.3%) 2/16 (12.5%) 1 
Pneumonia  25/28(95.3%) 9/12 (75.0%) 16/16 (100.0%) 0.067 
AKI 19/28 (67.9%) 9/12 (75.0%) 10/16 (62.5%) 0.687 
Need of dialysis  3/28 (10.7%) 0/12 (0.0%) 3/16 (18.8%) 0.238 
Treatment     
   - Lopinavir/Ritonavir 24/28 (85.7%) 9/12 (75.0%) 15/16 (93.8%) 0.285 
   - Hydroxicloroquine 27/28 (96.4%) 12/12 (100.0%) 15/16 (93.8%) 1 
   - Azithromycin 27/28 (96.4%) 11/12 (91.7%) 16/16 (100.0%) 0.429 
   - Tocilizumab 18/28 (64.3%) 6/12 (50.0%) 12/16 (75.0%) 0.243 
   - Steroids (bolus) 8/28 (28.6%) 3/12 (25.0%) 5/16 (31.3%) 1 
ICU Admission 8/28 (28.6%) 3/12 (25.0%) 5/16 (31.3%) 1 
Death  5/28 (17.9%) 0/12 (0.0%) 5/16 (31.3%) 0.053 
Length of stay 
   - At the Hospital 12.50 [8.25-19.50] 8 [4.25-13.50] 15.50 [12-25.50] 0.001 
   - At the Hotel / 9.50 [6.50-12.50] /  
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